Search

Learning from Game Theory to Improve Negotiations Skills

LEARNING FROM GAME THEORY TO IMPROVE NEGOTIATIONS SKILLS

Most new medicines are developed through a process of collaborative licensing agreements or acquisition. Significant negotiations underlie...

 
 
 
EvoNexus Gets Bank, Investment Firm Backing for Fintech Incubator

EVONEXUS GETS BANK, INVESTMENT FIRM BACKING FOR FINTECH INCUBATOR

Financial firms are facing competition from legacy players and disruptive fintech startups as technology continues to reshape the heavily...

FDA approves Roche's Tecentriq for first-line, extensive-stage small-cell lung cancer

FDA APPROVES ROCHE'S TECENTRIQ FOR FIRST-LINE, EXTENSIVE-STAGE SMALL-CELL LUNG CANCER

The PD-L1 inhibitor is the first new drug for ES-SCLC in more than 20 years. Meanwhile, Merck is also running a Phase III study of...

 
 
 
Bio Roundup: Golumbeski's Legacy, CRISPR Moratorium, Rebate Week & More

BIO ROUNDUP: GOLUMBESKI'S LEGACY, CRISPR MORATORIUM, REBATE WEEK & MORE

While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb's proposal to buy Celgene for $74 billion...

Clinical Analytics Platform TriNetX Raises $40M to Speed Drug Trials

CLINICAL ANALYTICS PLATFORM TRINETX RAISES $40M TO SPEED DRUG TRIALS

TriNetX, a Cambridge, MA developer of data analytics software for clinical research, has raised $40 million in a Series D funding round...

 
 
 
BIO2019 Education Programming Taking Shape

BIO2019 EDUCATION PROGRAMMING TAKING SHAPE

With the BIO International Convention only three months away, the finishing touches are being placed on its world-class education program....

 
 
 
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More

BIO ROUNDUP: NEW CRISPR FEUD, A NY SPLASH, PHARMA VS. CONGRESS & MORE

If you're into congressional spectacles, stay tuned later this month. A group of top biopharma executives-the full roster isn't known...

 
 
 
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More

BIO ROUNDUP: $74B FOR CELGENE, TWO CAR-T TALES, READY FOR SF & MORE

In 2018, my Exome colleagues and I published hundreds of stories about health, medicine, the biopharma industry, government policy,...

 
 
 
Bio Roundup: 2019 Trials, Pilgrim Price Chat, Pre-Xmas Sales & More

BIO ROUNDUP: 2019 TRIALS, PILGRIM PRICE CHAT, PRE-XMAS SALES & MORE

It's beginning to look a lot like, well, the last roundup of the year, with plenty of news to pack in before our holiday breather....

 
 
 
15 For '19: Key Clinical Data to Watch For Next Year

15 FOR '19: KEY CLINICAL DATA TO WATCH FOR NEXT YEAR

On Monday, Xconomy began our annual look ahead at clinical trials that could define biotech and have profound healthcare effects in...

Imfinzi looks flimsy in AstraZeneca's Phase III head and neck cancer study

IMFINZI LOOKS FLIMSY IN ASTRAZENECA'S PHASE III HEAD AND NECK CANCER STUDY

Results of the Phase III EAGLE study leave Merck's Keytruda and Bristol's Opdivo as the dominant players in the space of HNSCC after...

 
 
 
Bio Roundup: Moderna's IPO, Arena's Comeback, E-Cig Survey & More

BIO ROUNDUP: MODERNA'S IPO, ARENA'S COMEBACK, E-CIG SURVEY & MORE

Thanksgiving is around the corner and this week delivered a bounty of deals that have a number of life science companies expressing...

 
 
 
Medisafe to Get Paid For Health App's Performance

MEDISAFE TO GET PAID FOR HEALTH APP'S PERFORMANCE

More technology startups are embracing the healthcare industry's increasing willingness to pay for products based on how much they...